Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1977-5-12
pubmed:abstractText
Synthetic N-formylmethionyl peptides are chemotactic attractants for human polymorphonuclear leukocytes. The well-defined structure-activity relationship of these peptides in eliciting a chemotactic response suggests that the interaction of the peptides with a specific cellular binding site may initiate chemotaxis. By using tritiated N-formylmethionyl-leucyl-phenylalanine (fMet-Leu-[3H]Phe), a potent chemotactic peptide with high specific radioactivity, we have directly identified binding sites on human polymorphonuclear leukocytes. Binding of fMet-Leu-[3H]Phe to polymorphonuclear leukocytes is rapid (t1/2 less than 2 min) and reversible. The equilibrium dissociation constant (KD) for the interaction of fMet-Leu-[3H-A1Phe with the binding site is 12-14 nM at 37 degrees. The number of binding sites is approximately 2000 per cell. The specificity of the binding sites for a series of N-formylmethionyl peptides exactly reflects the specificity of the chemotactic response to the peptides in that they compete for the binding sites and initiate chemotaxis with the same order of potency (fMet-Leu-Phe greater than fMet-Met-Met greater than fMet-Phe greater than fMet-Leu greater than fMet),fPhe-Met is a competitive antagonist of the chemotactic activity of N-formylmethionyl peptides and has a calculated KD of 6x10-5 M. FPhe-Met also half-maximally inhibits binding of fMet-Leu[3H]Phe binding was the highest in polymorphonuclear leukocytes. No binding of fMet-Leu-[3H]Phe to human erythrocytes could be detected. These data indicate that fMet-Leu-[3H]Phe can be used to identify binding sites for chemotactic peptides on human polymorphonuclear leukocytes. It is likely that these binding sites initiate the specific response of motile cells to N-formylmethionyl peptides.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1065899, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1093163, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1127383, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1152991, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1245597, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-1262785, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-4175690, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-4179068, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-46841, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-4873021, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-4894, http://linkedlifedata.com/resource/pubmed/commentcorrection/265563-5232334
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:volume
74
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1204-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1977
pubmed:articleTitle
Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.